Results 91 to 100 of about 22,351 (243)
Frontiers in Medicine, 2022 Being introduced in 2010, fingolimod was among the first oral therapies for relapsing multiple sclerosis (MS). Since that time, postmarketing surveillance has noted several case reports of various cryptococcal infections associated with fingolimod use ...
Kent Carpenter +9 more
semanticscholar +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Epilepsia Open, EarlyView.Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source
A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation
Food Chemistry International, EarlyView.Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee +4 more
wiley +1 more source
Fingolimod Immune Effects Beyond Its Sequestration Ability [PDF]
, 2019 Fingolimod is the first orally administered drug approved for the treatment of relapsing-remitting multiple sclerosis (MS). This drug, modulating sphingosine receptors, regulates the trafficking of lymphocytes between primary and secondary lymphoid ...
Sica F., Centonze D., Buttari F.
core +1 more source
Effect of fingolimod on platelet count among multiple sclerosis patients
International Journal of Preventive Medicine, 2015 Background: While many studies have previously focused on fingolimod′s effect on immune cells, the effect it has on circulating and local central nervous system platelets (Plts) has not yet been investigated.
Mehrdad Farrokhi +7 more
doaj +1 more source
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Drugs in R&D, 2020 Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases.
Pablo Bascuñana +3 more
doaj +1 more source
PLoS ONE, 2021 ObjectiveTo describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.MethodsAn observational ...
J E Meca-Lallana +13 more
doaj +1 more source
International Journal of Cancer, EarlyView.ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang +10 more
wiley +1 more source
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives. [PDF]
, 2018 The immunomodulatory drug fingolimod (FTY720, Gilenya(R)) was approved for oral treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good tolerability. Pharmacologically, it acts as an unselective agonist of sphingosine
Zangemeister-Wittke, Uwe +3 more
core +1 more source
Antidepressant activity of fingolimod in mice [PDF]
, 2015 Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the
NICOLETTI, Ferdinando +26 more
core +2 more sources